Overcoming maternal antibody interference by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of swine influenza virus

Veterinary Microbiology

Volumn 118, Issue 1-2, 2006, Pages 67-75

  Wesley, Ronald D ^a   Lager, Kelly M ^a  

^a NATIONAL ANIMAL DISEASE CENTER   (United States)

Author keywords

Ad 5 vaccines; Maternal antibody interference; Swine influenza virus

Indexed keywords

HEMAGGLUTININ; INACTIVATED VACCINE; MATERNAL ANTIBODY; NUCLEOPROTEIN;

ACTIVE IMMUNIZATION; ADENOVIRUS VECTOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HEMAGGLUTINATION INHIBITION TEST; HUMAN ADENOVIRUS 5; INFLUENZA; INOCULATION; LUNG INJURY; LUNG LAVAGE; NONHUMAN; NOSE SECRETION; PROVOCATION TEST; SHAM FEEDING; SPECIES COMPARISON; SWINE; SWINE INFLUENZA VIRUS; THERAPY EFFECT; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VIRUS SHEDDING; VIRUS VIRULENCE;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, VIRAL; FEMALE; GENETIC VECTORS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; NUCLEOPROTEINS; ORTHOMYXOVIRIDAE INFECTIONS; RANDOM ALLOCATION; SWINE; SWINE DISEASES; VACCINATION; VACCINES, SYNTHETIC;

HUMAN ADENOVIRUS TYPE 5; SIMIAN IMMUNODEFICIENCY VIRUS; SUS SCROFA; SWINE INFLUENZA VIRUS;

EID: 33751003848     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetmic.2006.07.014     Document Type: Article

References (31)

1. Ambriovic A., Adam M., Monteil M., Paulin D., and Eloit M. Efficacy of replication-defective adenovirus-vectored vaccines: protection following intramuscular injection is linked to promoter efficiency in muscle representative cells. Virology 238 (1997) 327-335
2. Andrew M.E., Coupar B.E.H., Boyle D.B., and Ada G.L. The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants. Scand. J. Immunol. 25 (1987) 21-28
3. Berkner K.L. Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 6 (1988) 616-629
4. Brockmeier S.L., Lager K.M., Tartaglia J., Riviere M., Paoletti E., and Mengeling W.L. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses. Vet. Microbiol. 38 (1993) 41-58
5. Chengalvala M.V., Bhat B.M., Bhat R., Lubeck M.D., Mizutani S., Davis A.R., and Hung P.P. Immunogenicity of high expression adenovirus-hepatitis B virus recombinant vaccines in dogs. J. Gen. Virol. 75 (1994) 125-131
6. Easterday B.C., and Van Reeth K. Swine influenza. In: Straw B.E., D'Allaire S., Mengeling W.L., and Taylor D.J. (Eds). Diseases of Swine. 8th ed. (1999), Iowa State University Press, Ames, IA 277-290
7. Eloit M. Defective adenoviruses as virus vectors for veterinary vaccines. Vet. Res. 26 (1995) 207-208
8. Eloit M., Gilardi-Hebenstreit P., Toma B., and Perricaudet M. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. J. Gen. Virol. 71 (1990) 2425-2431
9. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus 5. J. Gen. Virol. 36 (1977) 59-74
10. Graham F.L., and Prevec L. Adenovirus-based expression vectors and recombinant vaccines. In: Ellis R.W. (Ed). Vaccines: New Approaches to Immunological Problems (1992), Butterworth-Heinemann, Woburn, MA 363-390
11. Grunhaus A., and Horwitz M.S. Adenoviruses as cloning vectors. Seminars Virol. 3 (1992) 237-252
12. Hitt M.M., and Graham F.L. Adenovirus vectors for human gene therapy. Adv. Virus Res. 55 (2000) 479-505
13. Janke B.H. Diagnosis of swine influenza. Swine Health Prod. 8 (2000) 79-84
14. Konishi E., Pincus S., Paoletti E., Laegreid W.W., Shope R.E., and Mason P.W. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology 190 (1992) 454-458
15. Lamb R.A., and Krug R.M. Othomyxoviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 4th ed. (2001), Lippincott Williams & Wilkins, Philadelphia 1487-1531
16. Larsen D.L., Karasin A., and Olsen C.W. Immunization of pigs against influenza virus infection by DNA vaccine priming followed by killed-virus vaccine boosting. Vaccine 19 (2001) 2842-2853
17. Le Potier M.F., Monteil M., Houdayer C., and Eloit M. Study of the delivery of the gD gene of pseudorabies virus to 1-day-old piglets by adenovirus or plasmid DNA as ways to by-pass the inhibition of the immune response by colostral antibodies. Vet. Microbiol. 55 (1997) 75-80
18. Macklin M.D., McCabe D., McGregor M.W., Neumann V., Meyer T., Callan R., Hinshaw V.S., and Swain W.F. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J. Virol. 72 (1998) 1491-1496
19. Mayr G.A., Chinsangaram J., and Grubman M.J. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 263 (1999) 496-506
20. Mayr G.A., O'Donnell V., Chinsangaram J., Mason P.W., and Grubman M.J. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 19 (2001) 2152-2162
21. Monteil M., Le Potier M.F., Cariolet R., Houdayer C., and Eloit M. Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth. J. Gen. Virol. 78 (1997) 3303-3310
22. Monteil M., Le Pottier M.F., Ristov A.A., Cariolet R., L'Hospitalier R., Klonjkowski B., and Eloit M. Single inoculation of replication-defective adenovirus-vectored vaccines at birth in piglets with maternal antibodies induces high level of antibodies and protection against pseudorabies. Vaccine 18 (2000) 1738-1742
23. Moraes M.P., Mayr G.A., Mason P.W., and Grubman M.J. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) stain A24. Vaccine 20 (2002) 1631-1639
24. Olsen C.W. The emergence of novel swine influenza viruses in North America. Virus Res. 85 (2002) 199-210
25. Prevec L., Schneider M., Rosenthal K.L., Belbeck L.W., Derbyshire J.B., and Graham F.L. Use of human adenovirus-based vectors for antigen expression in animals. J. Gen. Virol. 70 (1989) 429-434
26. Specter S., and Lancz G.J. Clinical Virology Manual (1986), Elsevier, New York pp. 193-195
27. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., Hawe L.A., Leander K.R., Martinez D., Perry H.C., Shiver J.W., Montgomery D.L., and Liu M.A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993) 1745-1749
28. Wesley R.D., Tang M., and Lager K.M. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 22 (2004) 3427-3434
29. Wesley R.D., and Lager K.M. Evaluation of a recombinant human adenovirus 5 vaccine administered via needle-free device and intramuscular injection for vaccination of pigs against swine influenza virus. Am. J. Vet. Res. 66 (2005) 1943-1947
30. Wraith D.C., Vessey A.E., and Askonas B.A. Purified influenza virus nucleoprotein protects mice from lethal infection. J. Gen. Virol. 68 (1987) 433-440
31. Yewdell J.W., Bennink J.R., Smith G.L., and Moss B. Influenza A nucleoprotein is a major antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 1785-1789